Your browser doesn't support javascript.
Antinuclear antibodies in individuals with COVID-19 reflect underlying disease: Identification of new autoantibodies in systemic sclerosis (CDK9) and malignancy (RNF20, RCC1, TRIP13).
Bossuyt, Xavier; Vulsteke, Jean-Baptiste; Van Elslande, Jan; Boon, Lise; Wuyts, Greet; Willebrords, Silke; Frans, Glynis; Geukens, Nick; Carpentier, Sebastien; Tejpar, Sabine; Wildiers, Hans; Blockmans, Daniel; De Langhe, Ellen; Vermeersch, Pieter; Derua, Rita.
  • Bossuyt X; Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium; Clinical and Diagnostic Immunology, Department of Microbiology, Immunology and Transplantation, KU, Leuven, Belgium. Electronic address: Xavier.bossuyt@uzleuven.be.
  • Vulsteke JB; Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, KU Leuven, Belgium; Rheumatology, University Hospitals Leuven, Leuven, Belgium.
  • Van Elslande J; Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium.
  • Boon L; Clinical and Diagnostic Immunology, Department of Microbiology, Immunology and Transplantation, KU, Leuven, Belgium.
  • Wuyts G; Clinical and Diagnostic Immunology, Department of Microbiology, Immunology and Transplantation, KU, Leuven, Belgium.
  • Willebrords S; Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium.
  • Frans G; Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium.
  • Geukens N; KU Leuven, PharmAbs: The KU Leuven Antibody Center, Herestraat 49 Box 820, 3000 Leuven, Belgium.
  • Carpentier S; SyBioMa, KU Leuven, Belgium.
  • Tejpar S; Laboratory of Molecular Digestive Oncology, Department of Oncology, KU Leuven, Leuven, Belgium; Department of Gastroenterology, University Hospitals Leuven, Belgium.
  • Wildiers H; Department of General Medical Oncology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
  • Blockmans D; General Internal Medicine, University Hospitals Leuven, Leuven, Belgium.
  • De Langhe E; Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, KU Leuven, Belgium; Rheumatology, University Hospitals Leuven, Belgium.
  • Vermeersch P; Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium; Department of Cardiovascular Sciences, KU Leuven, Leuven, Belgium.
  • Derua R; SyBioMa, KU Leuven, Belgium; Department of Cellular and Molecular Medicine, Laboratory of Protein Phosphorylation and Proteomics, KU Leuven, Belgium.
Autoimmun Rev ; 22(4): 103288, 2023 Apr.
Article in English | MEDLINE | ID: covidwho-2220460
ABSTRACT
A high prevalence of antinuclear antibodies (ANA) in COVID-19 has been insinuated, but the nature of the target antigens is poorly understood. We studied ANA by indirect immunofluorescence in 229 individuals with COVID-19. The target antigens of high titer ANA (≥1320) were determined by immunoprecipitation (IP) combined with liquid-chromatography-mass spectrometry (MS). High titer ANA (≥1320) were found in 14 (6%) of the individuals with COVID-19. Of the 14 COVID-19 cases with high titer ANA, 6 had an underlying autoimmune disease and 5 a malignancy. IP-MS revealed known target antigens associated with autoimmune disease as well as novel autoantigens, including CDK9 (in systemic sclerosis) and RNF20, RCC1 and TRIP13 (in malignancy). The novel autoantigens were confirmed by IP-Western blotting. In conclusion, in depth analysis of the targets of high titer ANA revealed novel autoantigens in systemic sclerosis and in malignant disease.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Scleroderma, Systemic / Autoimmune Diseases / COVID-19 / Neoplasms Type of study: Observational study Limits: Humans Language: English Journal: Autoimmun Rev Journal subject: Allergy and Immunology Year: 2023 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Scleroderma, Systemic / Autoimmune Diseases / COVID-19 / Neoplasms Type of study: Observational study Limits: Humans Language: English Journal: Autoimmun Rev Journal subject: Allergy and Immunology Year: 2023 Document Type: Article